Skip to content

Incidence of Depression and Its Complications After Surgical Site Infection - ISODEP.

Incidence of Depression and Its Complications After Surgical Site Infection - ISODEP.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07125196
Acronym
ISODEP
Enrollment
300
Registered
2025-08-15
Start date
2025-12-11
Completion date
2029-07-01
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Malnutrition, Surgical Site Infections

Keywords

surgical site infection, depression, malnutrition, orthopedic surgery, mood disorders, infection management, prospective study

Brief summary

Surgical-site infection (SSI) in orthopedic surgery is a serious and frequent complication with many consequences on the patient's quality of life. This study aims to describe the incidence of depression and its complications like malnutrition in patients followed for surgical site infection to allow their best management and prevention

Detailed description

We will conduct a monocentric (department orthopedic surgery, University Hospital of Bordeaux, France) prospective observational study for 5 years, involving all patients treated for surgical site infection (prosthetic surgery and trauma surgery) The data collected will concern the general condition of the patients, demographic data, information about septic condition, psychiatric disorders, or nutritional conditions, as well as the care provided. A three-year follow-up will be planned

Interventions

Exhaustive collection of data in a health data warehouse: collection of clinical, radiological examinations (standard of care), and self-administered questionnaire: a questionnaire concerning the psychological state of the patients (questionnaire according to DSM V) and a questionnaire on nutritional status.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient \>18 years old * Patient treated in infectiology for surgical site infection after orthopedic surgery of the limbs or spine: * Prosthetic limb surgery * Spinal surgery * Traumatology: Osteosynthesis of peripheral limbs or spine

Exclusion criteria

* Patient under guardianship or curatorship, * Pregnant, breastfeeding woman * Person deprived of liberty by judicial or administrative decision, * Person undergoing psychiatric treatment under duress requiring the consent of the legal representative. * Person unable to express their consent, * Person under legal protection, * Patient not affiliated to a social protection scheme. * Patient with a history of diagnosed depression, hospitalization for depressive disorders or taking mood-regulating treatments. * An initial BMI of less than \< 18.5, the existence a cancerous pathology, an ongoing inflammatory disease, a pathology responsible for chronic undernutrition

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Major Depressive EpisodesWeeks 6, Month 3, Month 6 and Month 12Incidence of major depressive episodes as defined by the DSM V criteria, screened using the Major Depression Inventory (MDI) score. This will be assessed at baseline (M0) and at subsequent follow-up visits (Weeks 6, Month 3, Month 6 and Month 12).

Secondary

MeasureTime frameDescription
Socio-Demographic and Clinical CharacteristicsBaseline (day 0) and 12 months (M12)Collection of socio-demographic data including age, sex, employment status, medical and surgical history, and smoking status at baseline and at the end of the study (M12).
Incidence of Malnutrition and Its Risk Factors12 months\- Malnutrition is defined by weight loss ≥ 5% in 1 month, ≥ 10% in 6 months, or ≥ 10% compared to usual weight before illness (HAS definition); BMI \< 18.5 kg/m².
Prognostic Significance of Malnutrition and Depression on Infection Treatment Efficacy and SafetyBaseline (Day 0), Week 6, Month 3, Month 6, and Month 12\- Success of infection treatment defined by the cessation of ongoing antibiotic therapy.

Countries

France

Contacts

CONTACTBenjamin BOUYER, PROF
b.bouyer@chu-bordeaux.fr+335 56 79 87 18
CONTACTRomain HUGUET
romain.huguet@chu-bordeaux.fr
PRINCIPAL_INVESTIGATORBenjamin BOUYER, PROF

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026